Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir

Cancer Gene Therapy
Suming WangC J Link

Abstract

Herpes simplex virus type-1 (HSV-1) has been demonstrated as a potentially useful gene delivery vector for gene therapy due to its high efficiency of in vivo transduction. The helper virus-dependent, HSV- 1 amplicon vectors were developed for easier operation and their larger capacity. In this study, the herpes simplex virus type-1 thymidine kinase (HSVtk) gene was cloned into the pHE700 amplicon vector to make an HE7tk vector and used for in vivo gene delivery. Human melanoma xenografts were established in athymic nude mice. Tumors were injected directly with HE7tk vector alone, HE7tk vector followed by ganciclovir (GCV), or a pHE700 amplicon vector carrying a green fluorescent protein (HE7GFP) gene followed by GCV. Efficient HSVtk transgene expression was found in the tumor 3 days after injection. Animals transduced with HE7tk followed by GCV had minimal tumor growth (P < .01 ). Animals that received either HE7tk vector without GCV or HE7GFP vector with GCV had some reduction in tumor growth compared to animals that were injected with buffer only. These data indicate that replication-defective HSV-1 amplicon vectors can be used effectively to deliver transgenes into solid tumors in vivo.

References

May 1, 1992·Journal of Virology·P A JohnsonT Friedmann
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A I Geller, A Freese
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A I GellerA B Pardee
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·S H ChenS L Woo
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·R ChambersR J Whitley
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·D Y HoR M Sapolsky
Aug 1, 1995·Molecular Biotechnology·J C GloriosoN DeLuca
Jan 1, 1995·Annual Review of Microbiology·J C GloriosoD J Fink
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·M MesnilH Yamasaki
Feb 10, 1997·Human Gene Therapy·K M JohnstonX O Breakefield
Feb 12, 1998·Gene Therapy·D M KriskyJ C Glorioso
Jan 13, 1998·Gene Therapy·S WangC J Link
Aug 8, 1998·Journal of Virology·T A Stavropoulos, C A Strathdee

❮ Previous
Next ❯

Citations

Aug 2, 2007·Expert Opinion on Biological Therapy·Delphine CuchetAlberto L Epstein
Sep 24, 2005·Melanoma Research·Lee D CranmerEvan M Hersh
Dec 4, 2009·Viruses·Suresh de Silva, William J Bowers
Sep 1, 2005·Apoptosis : an International Journal on Programmed Cell Death·N Hail
Mar 16, 2007·The Journal of Biological Chemistry·Jason KindrachukScott Napper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.